At the ACC meetings yesterday, several “late-breaking clinical trial” presentations provided substantial reasons to be enthusiastic about transcutaneous aortic valve replacement (TAVR) in comparison to standard surgical AV replacement (SAVR).
In the last few years the skeptical cardiologist finds himself inundated and sickened by slick promotional material from various hospitals across the country. These pamphlets typically tout the cutting edge
Anthony C. Pearson M.D., F.A.C.C. is a cardiologist, musician, writer and a regular columnist at MedPage Today